Recent findings from a retrospective cohort study of patients receiving anti-obesity pharmacotherapy, reporting that semaglutide was associated with a significantly lower risk for suicidal ideation compared to alternative, non-GLP-1 agonists, AOMs (55), provide some reassurance. Here, GLP1R is linked to obesity disorder.